Dr. Martens (DOCS) H1 2027 earnings summary

Executive summary

• H1 revenue was £290.4m reported and £292.4m at constant currency (CC), down 9.2% CC; hot weather, weaker boots and Europe DTC drove the decline.

• Adjusted EBIT was a £2.8m reported loss (£2.2m CC), versus £3.1m profit in H1 FY26; gross margin resilience and cost control partly cushioned lower sales.

• Strategy execution continued across consumer, product, markets and organisation; H2 peak trading is critical to FY27 results.

Financial highlights

• Revenue was £290.4m reported and £292.4m CC versus £322.0m in H1 FY26; total pairs sold fell 10.5% to 4.2m.

• Adjusted PBT was a £13.7m reported loss (£13.1m CC), versus a £9.4m loss in H1 FY26; reported PBT loss narrowed to £8.5m from £11.0m.

• Gross margin was 65.3% reported and 65.4% CC; adjusted operating costs fell 7.6% reported and 7.1% CC.

• Reported EBITDA rose 1.1% to £36.3m; adjusted basic EPS was (1.0)p reported and (0.9)p CC.

• Interim dividend was 0.85p per share, in line with policy.

Outlook and guidance

• H2 is the larger trading period; boots are expected to remain a headwind, and full-year results depend on peak trading in November, December and early January.

• FY27 guidance is unchanged: D&A ~£70m, net finance costs ~£24m, blended tax rate ~27%, capex ~£30m and net debt ~£200m including leases (~£50m net bank debt).

• Gross margin is expected to remain resilient in H2; U.S. pricing and lower tariff impacts continue but moderate, with price increases no longer comparable in Q4.

• Medium-term objectives remain profitable revenue growth above the relevant footwear market, mid-to-high-teens EBIT margin and strong cash generation; the directly operated store estate is expected to remain broadly flat over two years.

• Wholesale response ahead of the SS27 launch was encouraging; priorities include stabilising boots and building shoes momentum.